Identification and categorization of liver toxicity markers induced by a related pair of drugs

International Journal of Molecular Sciences

Volumn 12, Issue 7, 2011, Pages 4609-4624

  Chang, Ching Wei ^a   Beland, Frederick A ^a   Hines, Wade M ^b   Fuscoe, James C ^a   Han, Tao ^a   Chen, James J ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b BG Medicine Inc   (United States)

Author keywords

Biomarker; Entacapone; Genomic; Liver toxicity; Personalized medicine; Population heterogeneity; Tolcapone

Indexed keywords

5' NUCLEOTIDASE; ALANINE AMINOTRANSFERASE; ALBUMIN; AMINOACYL TRANSFER RNA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CREATININE; ENTACAPONE; GLUTAMATE DEHYDROGENASE; IDITOL DEHYDROGENASE; LACTATE DEHYDROGENASE; NITROGEN; PROTEIN; TOLCAPONE; UREA; VALINE TRANSFER RNA LIGASE; BENZOPHENONE DERIVATIVE; CATECHOL DERIVATIVE; NITRILE; NITROPHENOL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B3GAT2 GENE; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; BLOOD SAMPLING; CHST12 GENE; CONTROLLED STUDY; CYP21A1 GENE; DKK2 GENE; DRUG DOSE COMPARISON; DRUG MEGADOSE; GCK GENE; GENE; GENETIC ANALYSIS; GNAT3 GENE; IN VIVO STUDY; LIVER PARENCHYMA; LIVER TOXICITY; LOW DRUG DOSE; MALE; MFAP3 GENE; NONHUMAN; RAT; RNA SYNTHESIS; RT1 AW2 GENE; SOX17 GENE; STATISTICAL ANALYSIS; SULT1C2 GENE; TAS2R114 GENE; UREA NITROGEN BLOOD LEVEL; VARS2 GENE; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG-INDUCED LIVER INJURY; GENE REGULATORY NETWORK; LIVER; METABOLISM; TOXICITY;

ANIMALIA; RATTUS;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BENZOPHENONES; BILIRUBIN; BIOLOGICAL MARKERS; CATECHOLS; DRUG-INDUCED LIVER INJURY; GENE REGULATORY NETWORKS; LIVER; MALE; NITRILES; NITROPHENOLS; RATS; RNA, TRANSFER, AMINO ACYL;

EID: 79960786395     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12074609     Document Type: Article

References (35)

1. Abboud, G.; Kaplowitz, N. Drug-induced liver injury. Drug Saf. 2007, 30, 277-294.
2. Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005, 4, 489-499.
3. Zimmerman, H. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver; Lippincott Williams and Wilkins: Philadelphia, PA, USA, 1999.
4. Fung, M.; Thornton, A.; Mybeck, K.; Wu, J.; Hornbuckle, K.; Muniz, E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inf. J. 2001, 35, 293-317.
5. Kaplowitz, N. Drug-induced liver disorders: Implications for drug development and regulation. Drug Saf. 2001, 24, 483-490.
6. Lasser, K.E.; Allen, P.D.; Woolhandler, S.J.; Himmelstein, D.U.; Wolfe, S.M.; Bor, D.H. Timing of new black box warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 2002, 287, 2215-2220.
7. Temple, R.J.; Himmel, M.H. Safety of newly approved drugs. J. Am. Med. Assoc. 2002, 287, 2273-2275.
8. Shuster, D.; Laggner, C.; Langer, T. Why drugs fail-a study on side effects in new chemical entities. Curr. Pharm. Des. 2005, 11, 3545-3559.
9. Rotman, D. Can Pfizer deliver? Technol. Rev. 2004, 2, 58-65.
10. Boelsterli, U.A. Diclofenac-induced livery injury: A paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 2003, 192, 307-322.
11. McBurney, R.N.; Hines, W.M.; von Tungeln, L.S.; et al. The liver toxicity biomarker study: Phase I design and preliminary results. Toxicol. Pathol. 2009, 37, 52-64.
12. Chambers, J.M.; Cleveland, W.S.; Kleiner, B.; Tukey, P.A. Graphical Methods for Data Analysis; Springer: Berlin, Germany, 1983.
13. Gustafsson, J.A.; Libsoa, B.P. Studies on the metabolism of C21 steroids in rat liver. Hydroxylation of progesterone in rat liver microsomes. Eur. J. Biochem. 1970, 15, 525-530.
14. Abrams, W.R.; Ma, R.I.; Kucich, U.; Bashir, M.M.; Decker, S.; Tsipouras, P.; McPherson, J.D.; Wasmuth, J.J.; Rosenbloom, J. Molecular cloning of the microfibrillar protein MFAP3 and assignment of the gene to human chromosome 5q32-q33.2. Genomics 1995, 26, 47-54.
15. Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114, 147-152.
16. Kawaguchi, T.; Osatomi, K.; Yamashita, H.; Kabashima, T.; Uyeda, K. Mechanism for fatty acid "sparing" effect on glucose-induced transcription. Regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J. Biol. Chem. 2002, 277, 3829-3835.
17. Sharma, M.R.; Polavarapu, R.; Roseman, D.; Patel, V.; Eaton, E.; Kishor, P.B.; Nanji, A.A. Increased severity of alcoholic liver injury in female verses male rats: A microarray analysis. Exp. Mol. Pathol. 2008, 84, 46-58.
18. Takabatake, M.; Shibutani, M.; Dewa, Y.; Dewa, Y.; Nishimura, J.; Yasuno, H.; Jin, M.; Muguruma, M.; Kono, T.; Mitsumori, K. Concurrent administration of ascorbic acid enhances liver tumor-promoting activity of kojic acid in rats. J. Toxicol. Sci. 2008, 33, 127-140.
19. Welch, K.D.; Reilly, T.P.; Bourdi, M.; Hays, T.; Pise-Masison, C.A.; Radonovich, M.F.; Brady, J.N.; Dix, D.J.; Pohl, L.R. genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem. Res. Toxicol. 2006, 19, 223-233.
20. Haasio, K.; Sopanen, L.; Vaalavirta, L.; Linden, I.; Heinonen, E.H. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J. Neural Transm. 2001, 108, 79-91.
21. Haasio, K.; Koponen, A.; Penttila, K.E.; Nissinen, E. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. 2002, 453, 21-26.
22. Olanow, C.W. Tolcapone and hepatotoxic effects. Arch. Neurol. 2000, 57, 263-267.
23. Kohonen, T. Self-Organizing Maps, 3rd Ed.; Springer: Berlin, Germany, 2001.
24. Mootha, V.K.; Lindgren, C.M.; Eriksson, K.F.; Subramanian, A.; Sihag, S.; Lehar, L.; Puigserver, P.; Carlsson, E.; Ridderstråle, M.; Laurila, E. et al. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately down regulated in human diabetes. Nat. Genet. 2003, 34, 267-273.
25. Draghici, S.; Khatri, P.; Martins, R.P.; Ostermeiter, G.C.; Krawetz, S.A. Global functional profiling of gene expression. Genomics 2003, 81, 98-104.
26. Tian, L.; Greenberg, S.A.; Kong, S.W.; Altschuler, J.; Kohane, I.S.; Park, P.J. Discovering statistically significant pathways in expression profiling studies. Proc. Natl. Acad. Sci. USA 2005, 102, 13544-13549.
27. Tsai, C.; Chen, J. Multivariate analysis of variance test for gene set analysis. Bioinformatics 2009, 25, 897-903.
28. Kanehisa, M.; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28, 27-30.
29. Tong, W.; Cao, X.; Harris, S.; Sun, H.; Fang, H.; Fuscoe, J.; Harris, A.; Hong, H.; Xie, Q.; Perkins, R. et al. ArrayTrack-supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ. Health Perspect. 2003, 111, 1819-1826.
30. Mendrick, D.L. Genomic and genetic biomarkers of toxicity. Toxicology 2008, 245, 175-181.
31. Fielden, M.R.; Brennan, R.; Gollub, J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 2007, 99, 90-100.
32. Zidek, N.; Hellmann, J.; Kramer, P.J.; Hewitt, P.G. Acute hepatotoxicity: A predictive model based on focused illumina microarrays. Toxicol. Sci. 2007, 99, 289-302.
33. Man, W.J.; White, I.R.; Bryant, D.; Bugelski, P.; Camilleri, P.; Cutler, P.; Heald, G.; Lord, P.G.; Wood, J.; Kramer K. Protein expression analysis of drug-mediated hepatotoxicity in the Sprague-Dawley rat. Proteomics 2002, 2, 1577-1585.
34. Ulrich, R.G.; Rockett, J.C.; Gibson, G.G.; Pettit, S.D. Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. Environ. Health Perspect. 2004, 112, 423-427.
35. Mattes, W.B.; Pettit, S.D.; Sansone, S.A.; Bushel, P.R.; Waters, M.D. Database development in toxicogenomics: Issues and efforts. Environ. Health Perspect. 2004, 112, 495-505.